Fred Saad, MD, FRCS, presented “Response to Apalutamide Among Patients With Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC) From SPARTAN by DECIPHER Genomic Classifier Score” for the Grand Rounds in Urology audience in November 2019.
How to cite: Saad, Fred. “Response to Apalutamide Among Patients With Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC) From SPARTAN by DECIPHER Genomic Classifier Score” November, 2019. Accessed Apr 2026. https://grandroundsinurology.com/response-to-apalutamide-among-patients-with-nmcrpc-from-spartan-by-decipher-genomic-classifier-score/
Response to Apalutamide Among Patients With Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC) From SPARTAN by DECIPHER Genomic Classifier Score -Summary:
Fred Saad, MD, FRCS, presents findings from an exploratory analysis he led and presented at the American Urological Association’s 2019 Annual Meeting. The study evaluated the association between DECIPHER genomic classifier (GC) score and metastasis-free survival following apalutamide treatment in nonmetastatic castrate-resistant prostate cancer (nmCRPC) patients included in the SPARTAN study.
ABOUT THE AUTHOR
Fred Saad, MD, FRCS, CQ, FCAHS is a Professor and Chairman of the Department of Surgery at the University of Montréal in Quebec, Canada. Dr. Saad also holds the Raymond Garneau Chair in Prostate Cancer Research and is the Director of Clinical Research and the Molecular Oncology Research Laboratory in Prostate Cancer at the University of Montréal. His research interests include novel therapeutics in prostate cancer, molecular prognostic markers, and mechanisms of progression. He has over 40 clinical and basic research projects ongoing and has received over 50 million in research grants. Prof. Saad currently sits on over 15 steering committees of international clinical trials and serves on several guideline committees.
